Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and / or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Gynecologic

The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar HSIL (VIN 2 or VIN 3) associated with HPV types 16 and / or 18. VGX-3100 is being assessed as an alternative to surgery with the potential to clear the underlying HPV infection. For more information visit our study website at: www.VINresearchstudy.com
Gynecologic
II
Alvarez, Ronald
NCT03180684
VICCGYN17110

Pevonedistat and Azacitidine in Treating Patients with Refractory or Relapsed Myelodysplastic Syndrome or Myelodysplastic Syndrome / Myeloproliferative Neoplasm Who Fail Primary Therapy

Myelodysplastic Syndrome

This phase II trial studies how well pevonedistat and azacitidine work in treating patients with myelodysplastic syndrome or myelodysplastic syndrome / myeloproliferative neoplasm that have fails primary therapy and that does not respond to treatment or has come back. Pevonedistat and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Myelodysplastic Syndrome
II
Savona, Michael
NCT03238248
VICCHEM16146

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Multiple Cancer Types

The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Lung, Non Small Cell
II
Horn, Leora
NCT02706626
VICCTHO1736

An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

Multiple Cancer Types

This is an open-label, non-randomized Phase 1 / 2 safety study of INCAGN01876 in subjects with advanced or metastatic solid tumors that will be conducted in 2 parts. Part 1 will determine the pharmacologically active dose and / or maximum tolerated dose of INCAGN01876. Part 2 will further evaluate the recommended dose determined in Part 1 in subjects with select tumor types.
Kidney (Renal Cell), Lung, Melanoma, Miscellaneous, Non Small Cell, Uterine
I/II
Cardin, Dana
NCT02697591
VICCPHI1634

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors

The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
Not Available
I
Not Available
NCT02660034
VICCPHI1814

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

Multiple Cancer Types

This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, UCC, SCCHN and salivary gland cancer) not responding to standard therapy.
Colon, Head/Neck, Lung, Non Small Cell, Rectal, Urologic
I/II
Not Available
NCT02636036
VICCMD1762

A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma

Multiple Cancer Types

This is a two-arm, Phase 1b, open-label, dose escalation study of ME-401 alone and an open-label study of ME-401 in combination with rituximab in patients with relapsed / refractory B-cell malignancies.
Leukemia, Lymphoma
I
Reddy, Nishitha
NCT02914938
VICCHEM1714

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients with Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

This phase I / II trial studies the side effects of fludarabine phosphate, cyclophosphamide and total-body irradiation followed by donor bone marrow transplant and cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus in treating patients with primary immunodeficiency disorders or noncancerous inherited disorders. Giving low doses of chemotherapy and total-body irradiation before a bone marrow transplant helps prepare the patient’s body to accept the incoming donor’s bone marrow and decrease the risk that the patient's immune system will reject the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can attack the body's normal cells called graft versus host disease. Giving cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus after the transplant may help decrease this from happening.
Not Available
N/A
Connelly, James
NCT00358657
VICCNCPED1414

Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)

Multiple Cancer Types

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in subjects with advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab combination dose escalation phase and Part 2B cohort expansion phase. Part 2A GSK3359609 combinations with chemotherapy will only consist of safety run-in cohorts. Each part and phase of the study includes a screening period, a treatment period, and a follow-up period. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
Lung, Non Small Cell, Phase I
I
Horn, Leora
NCT02723955
VICCTHOP17113

Umbralisib and Ruxolitinib Phosphate in Treating Patients with Primary Myelofibrosis, Post-Polycythemia Vera MF, Post-Essential Thrombocythemia MF, Myelodysplastic / Myeloproliferative Neoplasm, or Polycythemia Vera

This phase I trial studies the side effects and best dose of umbralisib and ruxolitinib phosphate when given together in treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis (MF), post-essential thrombocythemia MF, myelodysplastic / myeloproliferative neoplasm or polycythemia vera. Umbralisib and ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Not Available
I
Savona, Michael
NCT02493530
VICCHEM1538

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: